echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Biotope bevacizumab injection authorized by Novartis subsidiary Sandoz

    Biotope bevacizumab injection authorized by Novartis subsidiary Sandoz

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 8, Biotech announced that the company signed a licensing and commercialization agreement with Novartis’ subsidiary Sandoz AG (hereinafter referred to as “Sandoz”) to sell the company’s BAT1706 (bevacizumab) injection in the United States, The exclusive product commercialization rights in Europe, Canada and most other international markets not covered by the BAT1706 cooperation are licensed to Sandoz for a fee


    The name of the transaction target: BAT1706 (bevacizumab) injection has exclusive product commercialization rights in the United States, Europe, Canada and most other international markets not covered by BAT1706 cooperation


    Transaction amount: The total amount of down payment and milestone payment is up to 155 million US dollars, including 27.


    Conditions for the agreement to enter into force: After both parties have signed and sealed and approved by Biotech’s board of directors, the matter does not need to be reviewed by the general meeting of shareholders


    Agreement performance period: The term of this agreement will begin on the effective date and will expire 15 years after the first commercial sale in each country's market


    BAT1706 is a monoclonal antibody developed by Biotec.


    The company submitted BAT1706 marketing authorization applications to China NMPA, US FDA and European EMA in 2020


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.